CYP2C19 GENOTYPES AND THERAPEUTIC DRUG MONITORING OF VORICONAZOLE IN PATIENTS WITH MULTIPLE MYELOMA

• At: AbuDhabi (United Arab Emirates) (2019)
• Type: Poster
• Poster code: POS-HPS-127
• By: TAN, Zhiyuan (Peking University Third Hospital, Pharmacy, China)
• Co-author(s): Zhiyuan Tan: Pharmacy, Peking University Third Hospital, BEIJING, China;Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, BEIJING, China
  Wei Liu: Pharmacy, Peking University Third Hospital, BEIJING, China;Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University, BEIJING, China
  Weilong Shi: Pharmacy , Peking University Third Hospital , BEIJING, China
  Kai Hu: Hematology, Peking University Third Hospital , BEIJING, China
  Rongsheng Zhao: Pharmacy, Peking University Third Hospital, BEIJING, China;Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University , BEIJING, China
  
• Abstract:

  Background

  New agents based intensive chemotherapy has improved the survival of multiple myeloma (MM), while invasive fungal diseases (IFD) are important causes of morbidity and mortality due to MM-related or treatment-related immunodeficiency. Voriconazole (VRZ) is a broad-spectrum first-line agent for IFD with favorable efficacy, but its..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login